These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 7602128)

  • 1. Characterization of a soluble, oligomeric HIV-1 gp160 protein as a potential immunogen.
    VanCott TC; Veit SC; Kalyanaraman V; Earl P; Birx DL
    J Immunol Methods; 1995 Jun; 183(1):103-17. PubMed ID: 7602128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein.
    Richardson TM; Stryjewski BL; Broder CC; Hoxie JA; Mascola JR; Earl PL; Doms RW
    J Virol; 1996 Feb; 70(2):753-62. PubMed ID: 8551612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities.
    Earl PL; Broder CC; Long D; Lee SA; Peterson J; Chakrabarti S; Doms RW; Moss B
    J Virol; 1994 May; 68(5):3015-26. PubMed ID: 7512157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determinants of human immunodeficiency virus type 1 envelope glycoprotein oligomeric structure.
    Poumbourios P; el Ahmar W; McPhee DA; Kemp BE
    J Virol; 1995 Feb; 69(2):1209-18. PubMed ID: 7815497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of recombinant gp120 and gp160 from HIV-1: binding to monoclonal antibodies and soluble CD4.
    Moore JP; McKeating JA; Jones IM; Stephens PE; Clements G; Thomson S; Weiss RA
    AIDS; 1990 Apr; 4(4):307-15. PubMed ID: 2190605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and epitope mapping of a recombinant soluble gp160 of the human immunodeficiency virus type 1 envelope glycoprotein.
    Pasquali JL; Kieny MP; Kolbe H; Christmann D; Knapp AM
    AIDS Res Hum Retroviruses; 1990 Sep; 6(9):1107-13. PubMed ID: 1702300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network.
    Montefiori DC; Graham BS; Zhou J; Zhou J; Bucco RA; Schwartz DH; Cavacini LA; Posner MR
    J Clin Invest; 1993 Aug; 92(2):840-7. PubMed ID: 8349820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improbability of harmful autoimmune responses resulting from immunization with HIV-1 envelope glycoproteins.
    Neurath AR; Strick N; Li YY; Jiang S
    AIDS Res Hum Retroviruses; 1993 Dec; 9(12):1195-208. PubMed ID: 8142138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Envelope sequence variability and serologic characterization of HIV type 1 group O isolates from equatorial guinea.
    Hunt JC; Golden AM; Lund JK; Gürtler LG; Zekeng L; Obiang J; Kaptué L; Hampl H; Vallari A; Devare SG
    AIDS Res Hum Retroviruses; 1997 Aug; 13(12):995-1005. PubMed ID: 9264286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fine specificity of the humoral immune response to HIV-1 GP160 in HIV-1 infected individuals from Tanzania.
    Nkya WM; Warren RQ; Wolf H; Hendrix CW; Tesha J; Redfield RR; Melcher GP; Burke DS; Kanda P; Kennedy RC
    J Med Virol; 1992 May; 37(1):61-6. PubMed ID: 1619399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160.
    VanCott TC; Mascola JR; Kaminski RW; Kalyanaraman V; Hallberg PL; Burnett PR; Ulrich JT; Rechtman DJ; Birx DL
    J Virol; 1997 Jun; 71(6):4319-30. PubMed ID: 9151820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal antibodies to the extracellular domain of HIV-1IIIB gp160 that neutralize infectivity, block binding to CD4, and react with diverse isolates.
    Nakamura GR; Byrn R; Rosenthal K; Porter JP; Hobbs MR; Riddle L; Eastman DJ; Dowbenko D; Gregory T; Fendly BM
    AIDS Res Hum Retroviruses; 1992 Nov; 8(11):1875-85. PubMed ID: 1283308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of antibody reactivity to human immunodeficiency virus type 1 (HIV-1) gp160 epitopes in sera from HIV-1-infected individuals from Tanzania and from the United States.
    Warren RQ; Nkya WM; Shao JF; Anderson SA; Wolf H; Hendrix CW; Kanda P; Wabuke M; Boswell RN; Redfield RR
    J Clin Microbiol; 1992 Jan; 30(1):126-31. PubMed ID: 1370844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of carbohydrate moieties on the immunogenicity of human immunodeficiency virus type 1 recombinant gp160.
    Benjouad A; Gluckman JC; Rochat H; Montagnier L; Bahraoui E
    J Virol; 1992 Apr; 66(4):2473-83. PubMed ID: 1347797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation and structural analysis of soluble oligomeric gp140 envelope proteins derived from neutralization-resistant and neutralization-susceptible primary HIV type 1 isolates.
    Stamatatos L; Lim M; Cheng-Mayer C
    AIDS Res Hum Retroviruses; 2000 Jul; 16(10):981-94. PubMed ID: 10890360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specificity of antibodies produced against native or desialylated human immunodeficiency virus type 1 recombinant gp160.
    Benjouad A; Gluckman JC; Montagnier L; Bahraoui E
    J Virol; 1993 Mar; 67(3):1693-7. PubMed ID: 7679751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of induction of antibodies specific for conserved, discontinuous epitopes of HIV-1 envelope glycoprotein by candidate AIDS vaccines.
    VanCott TC; Bethke FR; Burke DS; Redfield RR; Birx DL
    J Immunol; 1995 Oct; 155(8):4100-10. PubMed ID: 7561123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patterns of antibody reactivity to selected human immunodeficiency virus type 1 (HIV-1) gp160 epitopes infected individuals grouped according to CD4+ cell levels.
    Warren RQ; Wolf H; Zajac RA; Boswell RN; Kanda P; Kennedy RC
    J Clin Immunol; 1991 Jan; 11(1):13-21. PubMed ID: 1708780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of antibodies to the envelope protein of the human immunodeficiency virus by immunization with monoclonal anti-idiotypes.
    Zaghouani H; Goldstein D; Shah H; Anderson S; Lacroix M; Dionne G; Kennedy R; Bona C
    Proc Natl Acad Sci U S A; 1991 Jul; 88(13):5645-9. PubMed ID: 2062842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Presence of cross-reactive antibody between human immunodeficiency virus (HIV) and platelet glycoproteins in HIV-related immune thrombocytopenic purpura.
    Bettaieb A; Fromont P; Louache F; Oksenhendler E; Vainchenker W; Duédari N; Bierling P
    Blood; 1992 Jul; 80(1):162-9. PubMed ID: 1611083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.